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ABSTRACT
Introduction: The associations of chronic kid-
ney disease (CKD) severity, cardiovascular dis-
ease (CVD), and insulin with the risks of major
adverse cardiovascular events (MACE), mortal-
ity, and severe hypoglycemia in patients with
type 2 diabetes (T2D) at high cardiovascular
(CV) risk are not known. This secondary, pooled
analysis of data from the DEVOTE trial exam-
ined whether baseline glomerular filtration rate
(GFR) categories were associated with a higher
risk of these outcomes.
Methods: DEVOTE was a treat-to-target, dou-
ble-blind trial involving 7637 patients with T2D
at high CV risk who were randomized to once-
daily treatment with either insulin degludec
(degludec) or insulin glargine 100 units/mL
(glargine U100). Patients with estimated GFR
data at baseline (n = 7522) were analyzed fol-
lowing stratification into four GFR categories.
Results: The risks of MACE, CV death, and all-
cause mortality increased with worsening base-
line GFR category (P\0.05), with a trend
towards higher rates of severe hypoglycemia.
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Patients with prior CVD, CKD (estimated
GFR\ 60 mL/min/m2), or both were at higher
risk of MACE, CV death, and all-cause mortality.
Only CKD was associated with a higher rate of
severe hypoglycemia, and the risk of MACE was
higher in patients with CVD than in those with
CKD (P = 0.0003). There were no significant
interactions between randomized treatment
and GFR category.
Conclusion: The risks of MACE, CV death, and
all-cause mortality were higher with lower
baseline GFR and with prior CVD, CKD, or both.
The relative effects of degludec versus glargine
U100 on outcomes were consistent across
baseline GFR categories, suggesting that the
lower rate of severe hypoglycemia associated
with degludec use versus glargine U100 use was
independent of baseline GFR category.
Funding: Novo Nordisk.
Keywords: Basal insulin analogs;
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Key Summary Points
Why carry out this study?
There is limited evidence regarding the
associations of severity of chronic kidney
disease (CKD) with the risks of various
outcomes in patients with type 2 diabetes
(T2D).
Data are particularly limited for older
individuals with multiple comorbidities,
where the associations of coexisting CKD,
established cardiovascular disease (CVD),
and basal insulin with the risks of
outcomes are not clear.
Our secondary analysis from the DEVOTE
cardiovascular outcomes trial examined
whether baseline glomerular filtration rate
(GFR) categories or a prior medical history
of CKD, CVD, or both were associated
with higher risks of the above outcomes.
What was learned from the study?
In the DEVOTE cohort of patients at high
cardiovascular risk, worsening baseline
GFR categories were associated with
progressively higher risks of
cardiovascular events and death, with a
trend towards higher rates of severe
hypoglycemia. There were no significant
interactions between randomized
treatment and GFR category, although
consistently lower rates of severe
hypoglycemia were observed with
degludec compared with glargine U100,
regardless of prior CVD or prior CKD
(there was no significant difference for
those without prior CVD).
The relative effects of degludec and
glargine U100 on cardiovascular outcomes
were consistent across the baseline GFR
categories, suggesting that the lower rates
of severe hypoglycemia observed with
degludec versus glargine U100 were
independent of baseline GFR category
(there were only significant differences for
GFR categories G2 and G3).
Considering that there was an observed
association between baseline GFR
category and risk of death regardless of
randomized basal insulin assignment, a
better understanding of this association
and methods to mitigate the incremental
risk associated with declining GFR remain
important clinical objectives.
INTRODUCTION
Cardiovascular disease (CVD) and chronic kid-
ney disease (CKD) are highly prevalent comor-
bidities in patients with type 2 diabetes (T2D)
[1, 2]. Both are associated with an increased risk
of death [3–6].
Historically, cardiovascular outcomes trials
(CVOTs) have excluded patients with CKD [7],
while standard trials of antihyperglycemic
therapies have typically enrolled cohorts of
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younger patients at a lower risk of cardiovas-
cular events [8]. However, as a result of
industry guidance, CVOTs for new antihy-
perglycemic therapies now include patients at
high risk of cardiovascular events (including
those with CVD or CKD) [9, 10]. Recently,
results from a number of CVOTs (and sec-
ondary analyses) of patients with T2D have
been published that demonstrate the poten-
tial for some antihyperglycemic therapies to
improve cardiovascular and/or renal out-
comes [11–15]. Some of these CVOTs have also
compared the effects of treatment on cardio-
vascular outcomes in patients with T2D strat-
ified by baseline estimated glomerular
filtration rate (eGFR) [11, 14, 16].
Antihyperglycemic medications in patients
with differing levels of renal function can affect
treatment efficacy and safety; for instance, they
can lead to an increased risk of hypoglycemia
[11] and/or increased risks of cardiovascular
events and mortality [17–23], resulting in pro-
duct-label cautions, warnings, and contraindi-
cations [11, 24]. As patients with a lower
glomerular filtration rate (GFR) tend to have a
higher burden of CVD, a longer duration of
T2D, and more commonly require insulin
therapy [11, 14], there is a need to better
understand the relationships between CKD and
CVD risk factors, outcomes, and the use of
medications in this population (particularly
those with severe CKD who have been excluded
from most trials) [11].
DEVOTE, a CVOT comparing insulin deglu-
dec (degludec) and insulin glargine 100 units/
mL (glargine U100) in a population at high
cardiovascular risk and renal risk, presents an
opportunity to evaluate cardiovascular out-
comes in insulin-treated patients with T2D
along with CVD and/or CKD [25]. Thus, the
present analyses evaluated the associations of
baseline GFR category, prior CVD, and/or prior
CKD with the risks of major adverse cardiovas-
cular events (MACE), cardiovascular death, all-
cause mortality, and severe hypoglycemia. They
also examined whether randomized treatment




The secondary analyses described below utilized
data from the DEVOTE CVOT. Detailed
descriptions of the protocol, methods, and pri-
mary results have been published previously
[25, 26]. In brief, DEVOTE was a multicenter,
prospective, treat-to-target, randomized, double-
blind, active comparator CVOT that was
designed to continue until at least 633 MACE
(as confirmed by a central, blinded Event
Adjudication Committee, EAC) had accrued.
DEVOTE is registered with ClinicalTrials.gov
(NCT01959529) and was conducted in accor-
dance with the Declaration of Helsinki and the
Good Clinical Practice Guideline of the Inter-
national Council for Harmonisation of Techni-
cal Requirements for Pharmaceuticals for
Human Use [27, 28]. The protocol was approved
by an independent ethics committee or insti-
tutional review board for each center; written
informed consent was obtained from each
patient before any trial-related activities were
performed.
Patients and Treatments
Patients eligible for inclusion in DEVOTE were
those who had T2D treated with at least one
oral or injectable antihyperglycemic agent and
had glycated hemoglobin (HbA1c) levels
C 7.0% (53 mmol/mol) or\7.0% and treated
with C 20 units/day of basal insulin. In the
present analyses comparing patients by baseline
renal function, only patients with eGFR data at
baseline/time of randomization were included.
In DEVOTE, patients were randomized 1:1 to
receive either degludec or glargine U100 (both
in identical 100-U/mL, 10-mL vials) blinded,
administered by subcutaneous injection once
daily between the evening meal and bedtime, in
addition to the standard of care. Patients were
eligible if they had a medical history of either at
least one coexisting cardiovascular or renal
condition and were aged C 50 years, or if they
had at least one among a range of pre-specified
cardiovascular risk factors (microalbuminuria or
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proteinuria; hypertension and left ventricular
hypertrophy identified by electrocardiogram or
imaging; or left ventricular systolic and diastolic
dysfunction identified by imaging or ankle/
brachial index\0.9) and were aged C 60 years
[26]. All patients were allowed to continue their
pre-trial antihyperglycemic therapy with the
exception of basal and premix insulins, which
were discontinued.
Outcomes
The main outcomes in the present analyses
were as per the primary analysis in DEVOTE
[26]. The primary composite MACE outcome
was time to first occurrence of EAC-confirmed
cardiovascular death, nonfatal myocardial
infarction, or nonfatal stroke. Secondary out-
comes included time to EAC-confirmed all-
cause mortality and the number of EAC-con-
firmed severe hypoglycemic events. Severe
hypoglycemia was defined in accordance with
the American Diabetes Association criteria as an
episode requiring the assistance of another
person to actively administer carbohydrate or
glucagon or to take other corrective actions
[29]. Other secondary outcomes included the
HbA1c level achieved, the fasting plasma glu-
cose (FPG), and the self-measured blood glucose
(SMBG).
Statistical Analysis
In a set of pre-planned analyses, patients were
grouped by baseline GFR category according to
their baseline renal function as defined by the
Kidney Disease: Improving Global Outcomes
guidelines [30]:
• GFR category G1 (C 90 mL/min/1.73 m2,
normal function)
• GFR category G2 (60–\90 ml/min/1.73 m2,
mild impairment)
• GFR category G3 (30–\ 60 mL/min/1.73 m2,
moderate impairment)
• GFR category G4–5 (\ 30 mL/min/1.73 m2,
severe impairment).
Patients with a baseline GFR category of G4
(n = 207) or G5 (n = 7) were combined to ensure
a sufficient number of patients and events in
these categories were included for comparison
with other categories. The reference group for
comparison of outcomes was G1, as these
patients were those with a normal baseline
eGFR. Patient outcomes were also evaluated
according to randomized treatment by baseline
GFR category.
Comparisons between GFR categories, treat-
ment differences within each GFR category, and
the interaction between treatment and GFR
category were investigated for all outcomes.
Analyses of outcomes were all pre-specified
except for the evaluation of the interaction
between treatment and prior CKD (defined as
eGFR\ 60 mL/min/1.73 m2 at baseline) [30]
and/or prior CVD at baseline (according to
medical history) as well as the analyses of out-
comes as a function of baseline eGFR (as a
continuous measure). Analyses investigating
the associations of prior CVD and/or prior CKD
with outcomes utilized a pooled population
(i.e., independent of the randomized treatment)
of all patients with CVD (with and without
CKD) or with CKD (with and without CVD). In
addition, supplementary analyses compared the
associations with outcomes in patients with
prior CVD only to those with prior CKD only.
Time from randomization to first MACE,
cardiovascular death, and all-cause mortality
were analyzed using Cox proportional hazard
regression models with treatment, baseline GFR
category, and interaction between treatment
and baseline GFR category as fixed factors. The
number of severe hypoglycemic events was
analyzed using a negative binomial regression
model with log-link function and the logarithm
of the observation time (100 patient years) as
offset in addition to randomized treatment,
baseline GFR category, and their interactions.
Additionally, for all the endpoints mentioned
above, the interaction effect was dropped from
the corresponding models to obtain pooled
contrasts for baseline GFR category. In the
analysis of the cardiovascular component of the
MACE outcome, any patient whose first event
was death from noncardiovascular causes was
censored at their time of death.
Sensitivity analyses of all the pre-specified
analyses were conducted following adjustment
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for the following additional baseline covariates:
sex, geographical region, age, diabetes duration,
cardiovascular risk stratum, insulin use, and
smoking status.
The relationship between baseline GFR and
the proportion of events during 1 year was
modeled by polynomials of up to five degrees,
with the best model selected using Akaike’s
information criterion [31].
Changes in HbA1c and FPG from baseline to
24 months by baseline GFR category were ana-
lyzed with a mixed-effects model for repeated
measures (MMRM) within participants, using an
unstructured residual covariance matrix among
visits. Besides randomized treatment and base-
line GFR category, the MMRM included a fixed
effect for the baseline measure of the given
outcome.
Interactions between visit and treatment, visit
andGFR category, and visit andfirst dosewere also
included as fixed effects, as was the three-way
interaction (treatment 9 GFR 9 visit). Thepooled
treatment population differences in change from
baselineHbA1c and FPGwere analyzed bybaseline
GFR category using the same model with interac-
tions between visit and treatment, visit and GFR
category, and visit and baseline included as fixed
effects, but without the three-way interaction
effect. Total insulin dose (U/kg) at 24 months was
analyzed by GFR category using the same MMRM
as above, but using an unstructured residual
covariancematrixamongvisits at3, 6, 9, 12, 15,18,
21, and 24 months,with log(first dose) included as
a fixed effect.
A two-sided P value of less than 0.05 was
considered statistically significant, although it
was not multiplicity adjusted (SAS version 9.4,
SAS Institute, Cary, NC, USA). All statistical
analyses by randomized treatment assignment
followed the intention-to-treat principle.
RESULTS
Patients
The median observation time in DEVOTE was
2.0 years for both treatments. In the pre-planned
analyses from DEVOTE (n = 7637), data on base-
line eGFR were available for 98% of patients
(n = 7522). Similar to the overall DEVOTE cohort,
this population consisted of approximately equal
numbers of patients randomized to treatment
with degludec (n = 3765) or glargine U100
(n = 3757). In the total population (n = 7637),
established CVD (72%) was more common than
CKD (38%) at baseline. Furthermore, the presence
of both prior CVD and prior CKD (25%) was more
common than the absence of both (15%).
Comparing baseline characteristics and
demographics across baseline GFR categories,
patients with worse GFR categories were older,
had a longer diabetes duration, included a lower
proportion of males, had lower HbA1c levels,
had higher body mass index (BMI) values, and
were more likely to have established CVD/CKD
(Table 1). Patients with worse GFR categories
were also more likely to use insulin, angio-
tensin-receptor blockers, diuretics, and lipid-
modifying drugs. In contrast, metformin and
angiotensin-converting enzyme inhibitor use
was more common in patients with less
advanced GFR categories. Detailed comparisons
of these data are provided in the supplementary
results in the Electronic supplementary material
(ESM), as are descriptions of baseline blood
pressure and potassium levels.
Cardiovascular and Mortality Outcomes
Worse baseline GFR categories were associated
with numerically higher risks of MACE, cardio-
vascular death, and all-cause mortality. Com-
pared with patients with normal baseline eGFR
(G1), risks were significantly higher for MACE
(G3–5), cardiovascular death (G2–5), and all-
cause mortality (G2–5) (Figs. 1, 2). Cardiovas-
cular death accounted for 66% of all-cause
mortality (n = 277/422), with similar contribu-
tions seen for all baseline GFR categories
(63–69%). Cardiovascular death accounted for
41% of all MACE (n = 277/671); this increased
from 27% in patients with GFR category G1 to
36, 50, and 53% in patients with GFR categories
G2, G3, and G4–5, respectively. When evaluat-
ing outcomes using baseline eGFR as a contin-
uous variable, the risks of MACE, all-cause
mortality, and cardiovascular death were higher
in patients with lower eGFR, but the relation-
ship was nonlinear (Fig. S1 in the ESM).
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Table 1 Baseline characteristics




G2 (60 to < 90)
GFR category
G3 (30 to < 60)
GFR categories
G4–5 (< 30)
Number of patients (n) 1486 3118 2704 214
Age (years) 60.0 (± 5.7) 65.0 (± 6.7) 67.5 (± 7.5) 66.9 (± 7.4) \0.001
Male (%) 63.8 65.0 60.7 47.2 –
Ethnicity (%)
Hispanic or Latino 17.4 15.0 13.5 13.6 –
Race (%)
White 72.3 76.3 76.9 73.4 –
Black or African American 12.2 10.1 10.7 11.7 –
Asian 12.3 10.0 9.3 11.2 –
Other 3.1 3.5 3.1 3.7 –
Region (%)
Europe 16.2 13.2 7.5 6.1 –
North America 60.7 66.7 75.5 71.5 –
South America 8.1 8.6 6.4 7.5 –
Asia excluding India 3.5 3.9 4.0 4.2 –
India 7.0 4.3 3.8 6.5 –
Africa 4.4 3.3 2.8 4.2 –
Diabetes duration (years) 13.8 (± 7.5) 15.9 (± 8.7) 18.2 (± 9.2) 19.7 (± 10.1) \0.001
Body weight (kg) 94.6 (23.3) 95.5 (22.3) 97.5 (23.1) 97.4 (24.4) \0.001














Pulse (beats/minute) 75.0 (± 11.1) 73.5 (± 11.2) 71.7 (± 11.4) 71.1 (± 11.2) \0.001
Plasma potassium (mEq/L) 4.5 (± 0.0) 4.6 (± 0.0) 4.7 (± 0.0) 5.0 (± 0.1) –
HbA1c (%) 8.8 (± 1.8) 8.4 (± 1.6) 8.3 (± 1.6) 8.2 (± 1.7) \0.001
HbA1c (mmol/mol) 72.9 (19.5) 68.3 (17.8) 66.9 (17.1) 65.8 (18.1) \0.001
Fasting plasma glucose
(mg/dL)
181.5 (± 70.1) 170.5 (± 69.3) 167.7 (± 70.5) 169.9 (± 82.6) \0.001
Hemoglobin (g/dL) 13.8 (± 1.4) 13.6 (± 1.4) 13.0 (± 1.6) 12.1 (± 1.6) –
Serum albumin (g/dL) 4.3 (± 0.3) 4.2 (± 0.3) 4.2 (± 0.3) 4.1 (± 0.4) –
Total cholesterol (mg/dL) 168.3 (± 50.1) 163.1 (± 45.5) 165.6 (± 47.1) 164.9 (± 47.8) 0.016
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Table 1 continued




G2 (60 to < 90)
GFR category





89.3 (± 37.5) 84.1 (± 35.1) 85.0 (± 37.4) 84.7 (± 36.1) \0.001
High-density lipoprotein
cholesterol (mg/dL)
44.4 (± 12.5) 44.6 (± 12.9) 44.2 (± 13.1) 44.1 (± 12.1) –
Triglycerides (mg/dL) 185.5 (± 193.2) 180.5 (± 160.3) 190.0 (± 142.1) 186.2 (± 115.5) \0.001
Current smokers (%) 16.5 11.9 7.4 9.8 –
Established CVD/CKD
(%)




25.5 31.6 36.8 44.4 –
eGFR (mL/min/1.73 m2) 97.7 (± 6.0) 74.7 (± 8.8) 47.2 (± 8.0) 25.4 (± 4.1) \0.001
Creatinine} (mg/dL) 0.8 (± 0.1) 1.0 (± 0.2) 1.4 (± 0.3) 2.3 (± 0.5) –
Antihyperglycemic treatment (excluding insulins; %)
Metformin 77.2 69.7 42.5 15.9
Sulfonylureas 30.3 29.1 29.6 21.0
Alpha-glucosidase
inhibitors
2.0 1.9 1.5 0.5
Thiazolidinediones 2.4 3.5 4.2 2.3
Dipeptidyl peptidase-4
inhibitors
11.6 12.4 12.9 13.1
Glucagon-like peptide-1
receptor agonists
8.5 7.9 7.8 7.5
Sodium-dependent glucose
transporter-2 inhibitors
1.9 2.4 2.1 0.9
Insulins (%)
Long-acting 56.4 58.3 63.1 71.0
Intermediate-acting 14.3 14.4 13.9 11.2
Short-acting 32.4 34.6 41.1 48.6
Premix 10.7 9.8 10.4 11.7
Antihypertensive therapy§
(%)
90.6 92.6 94.9 96.3
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There were no significant interactions
between randomized treatment (degludec ver-
sus glargine U100) and baseline GFR category
for MACE, cardiovascular death, or all-cause
mortality (Fig. 3).
Severe Hypoglycemia
There was a nonsignificant trend towards
higher rates of severe hypoglycemia with more
advanced baseline GFR category (Figs. 1, 2),
with the risk of severe hypoglycemia increasing
Table 1 continued




G2 (60 to < 90)
GFR category
G3 (30 to < 60)
GFR categories
G4–5 (< 30)
Beta blockers 54.9 56.8 60.0 60.7
Calcium channel blockers 26.4 30.1 36.7 46.7
Angiotensin-converting
enzyme inhibitors
50.3 48.7 45.8 30.8
Angiotensin receptor
blockers
29.3 32.2 35.9 47.2
Others 6.0 8.6 13.3 22.0
Diuretics§ (%) 36.0 45.7 60.2 76.2
Loop diuretics 13.5 17.1 31.7 53.7
Thiazides 18.0 23.0 25.4 22.4
Lipid-modifying
medications§ (%)
78.7 81.8 84.4 85.0
Statins 75.9 78.5 79.9 83.2
Fibrates 6.9 10.0 14.4 15.9
Ezetimibe 3.7 4.7 4.9 3.7
Platelet aggregation
inhibitors§ (%)
73.3 73.1 70.3 65.4
Acetylsalicylic acid 66.8 66.4 63.8 60.3
Antithrombotic
medication§ (%)
4.8 6.6 10.7 10.3
Data listed are number, proportion (%), or mean (± standard deviation). Data are arithmetic means of observed values
CKD chronic kidney disease, CVD cardiovascular disease, eGFR estimated glomerular filtration rate, HbA1c glycated
hemoglobin
*GFR categories G1–5 were defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines
[30]
 Six patients had missing drug initiation dates; they were assumed to be on treatment at baseline
 Pre-trial insulin treatment
§ Nine patients had missing drug initiation dates; they were assumed to be on treatment at baseline
} Conversion factor for serum creatinine in mg/dL to lmol/L, 9 88.4. A total of 115 patients had missing baseline eGFR
data and were removed from the analysis
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with decreasing baseline eGFR (Fig. S1 in the
ESM). There was no evidence of heterogeneity
regarding the association between randomized
treatment and baseline GFR category for severe
hypoglycemia, as illustrated by the nonsignifi-
cant interaction (P = 0.9; Fig. 3).
Sensitivity Analyses of MACE, All-Cause
Mortality, and Severe Hypoglycemia
The sensitivity analyses adjusting for baseline
covariates were broadly consistent with the
results of the primary analyses (Table S1 in the
ESM). However, after adjustment, compared
with patients with GFR category G1, patients
with GFR category G2 no longer had signifi-
cantly higher risks of cardiovascular death or
all-cause mortality, and patients with GFR cat-
egory G3 no longer had a significantly higher
rate of severe hypoglycemia.
Associations of Prior CVD and Prior CKD
with the Risks of MACE, Cardiovascular
Death, All-Cause Mortality, and Severe
Hypoglycemia
Patients with either prior CVD or prior CKD
were at higher associated risk of MACE, cardio-
vascular death, and all-cause mortality than
those without a history of either of these
Fig. 1 Risks of various outcomes by baseline GFR category
relative to GFR category G1. *Rate of events/100 patient
years of exposure. GFR category G1 (solid circle) was used
as the reference for GFR categories G2, G3, and G4–5
(open circles). Time from randomization to first MACE,
cardiovascular death, and all-cause mortality were analyzed
using Cox proportional hazard regression models with
treatment, baseline GFR category, and interaction between
treatment and baseline GFR category as fixed factors. The
number of severe hypoglycemic events was analyzed using a
negative binomial regression model with log-link function
and the logarithm of the duration of observation time (100
patient years) as offset in addition to randomized
treatment, baseline GFR category, and their interactions.
Data on the proportion of patients with events and the
rate of severe hypoglycemic events are based on observed
numbers. CI confidence interval, CV cardiovascular, GFR
glomerular filtration rate, MACE major adverse cardiovas-
cular events
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conditions (Fig. 4). In contrast, only prior CKD
was associated with a significantly higher rate of
severe hypoglycemia (Fig. 4).
Upon comparing outcomes in patients with
CVD only to those with CKD only, prior CVD
was found to be associated with a higher risk of
MACE than prior CKD (P = 0.0003), but there
were no significant differences between patients
with prior CVD and patients with prior CKD in
the risks of cardiovascular death (P = 0.6), all-
cause mortality (P = 0.2), and severe hypo-
glycemia (P = 0.1; Fig. S2 in the ESM).
A significantly higher risk of each outcome
was consistently observed in patients with both
prior CVD and prior CKD as compared with
patients with neither of these conditions or
with prior CVD alone (MACE, cardiovascular
death, all-cause mortality: all P \0.0001; severe
hypoglycemia: P = 0.04 and P = 0.002, respec-
tively; Fig. S2 in the ESM).
There were no significant interactions
between randomized treatment and the associ-
ation of prior CVD or prior CKD with MACE
(P = 0.6 and 0.8, respectively), cardiovascular
death (P = 0.2 and 0.9, respectively), all-cause
mortality (both P = 0.2), or severe hypo-
glycemia (P = 0.09 and 0.6, respectively; Fig. 5).
In addition to an absence of significant inter-
actions, there were also no significant associa-
tions between randomized treatment and prior
CVD status or prior CKD groups for MACE,
cardiovascular death, and all-cause mortality.
Regardless of whether patients had prior CVD or
prior CKD, the rate of severe hypoglycemia was
consistently lower with degludec than with
glargine U100 except in patients with no prior
CVD (Fig. 5). A more detailed exploration of the
associations between a history of CVD or CKD
and these outcomes is provided in Figs. S2 and
S3 of the ESM.
Fig. 2 Kaplan–Meier plots for a time to first MACE,
b time to cardiovascular death, c time to all-cause
mortality, and d number of severe hypoglycemic events
by baseline GFR category. GFR glomerular filtration rate,
MACE major adverse cardiovascular events
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Efficacy Measures
In general, differences in SMBG and changes in
HbA1c and FPG were absent between baseline
GFR categories G2–G5, with the exception of a
lower total insulin dose (U/kg) in patients with
a more advanced baseline GFR category (G1:
0.85, 95% confidence interval [CI] 0.82–0.89;
G2: 0.76, 95% CI 0.74–0.78; G3: 0.69, 95% CI
0.67–0.71; G4–5: 0.61, 95% CI 0.54–0.68; see
the supplementary results and Fig. S4 in the
ESM).
DISCUSSION
These secondary analyses from DEVOTE
demonstrate that patients with a more
advanced baseline GFR category were at greater
risk of MACE, cardiovascular death, and all-
cause mortality as compared with those in the
normal baseline GFR category. In addition,
severe hypoglycemia tended to be more com-
mon, albeit not significantly so, in patients with
a more advanced baseline GFR category.
Patients with either prior CVD or prior CKD
had higher risks of MACE, cardiovascular death,
and all-cause mortality than those without
Fig. 3 Comparisons of associations of treatment with
degludec or glargine U100 with the risks of MACE,
cardiovascular death, and all-cause mortality and the rate
of severe hypoglycemia by baseline GFR category. *P value
for the interaction between treatment and baseline GFR
category;rate of events/100 patient years of exposure.
Time from randomization to first MACE, cardiovascular
death, and all-cause mortality were analyzed using Cox
proportional hazard regression models with treatment,
baseline GFR category, and interaction between treatment
and baseline GFR category as fixed factors. The number of
severe hypoglycemic events was analyzed using a negative
binomial regression model with log-link function and the
logarithm of the duration of observation time (100 patient
years) as offset in addition to randomized treatment,
baseline GFR category, and their interactions. Data on the
proportion of patients with events and the rate of severe
hypoglycemic events are based on observed numbers. The
MACE and severe hypoglycemia analyses have already been
published [25]. CI confidence interval, GFR glomerular
filtration rate, glargine U100 insulin glargine 100 units/
mL, MACE major adverse cardiovascular events
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these conditions, while those with both had the
highest risks of these outcomes compared with
those without prior CVD and prior CKD or
those with only prior CVD. Patients with prior
CVD had a significantly higher risk of MACE
compared with those with prior CKD, and only
prior CKD was associated with a significantly
higher rate of severe hypoglycemia. When
patients with prior CVD only were compared to
those with prior CKD only, the risks of cardio-
vascular death and all-cause mortality were
similar in both groups, despite the presence of a
stronger association with CKD than with CVD.
The similar effects of randomized treatment
across the GFR categories, together with the lack
of significant interactions of baseline GFR cate-
gory with randomized treatment for MACE,
cardiovascular death, or all-cause mortality
suggest that the type of basal insulin treatment
applied did not affect the associations between
GFR severity and outcomes. That is, regardless
of the baseline GFR category, the results are
consistent with those from the primary
DEVOTE analyses [25], where the risks of MACE,
cardiovascular death, and all-cause mortality
were not found to differ significantly between
Fig. 4 Comparison of associations of prior CVD/CKD
and no prior CVD/CKD with the risks of MACE,
cardiovascular death, and all-cause mortality and the rate
of severe hypoglycemia. *Rate of events/100 patient years
of exposure. A more detailed exploration of the impact of a
history of CVD or CKD on these outcomes is available in
the ESM. Time from randomization to first MACE,
cardiovascular death, and all-cause mortality were analyzed
using Cox proportional hazard regression models with
treatment, baseline GFR category, and interaction between
treatment and baseline GFR category as fixed factors. The
number of severe hypoglycemic events was analyzed using a
negative binomial regression model with log-link function
and the logarithm of the duration of observation time (100
patient years) as offset in addition to randomized
treatment, baseline GFR category, and their interactions.
Data on the proportion of patients with events and the
rate of severe hypoglycemic events are based on observed
numbers. CI confidence interval, CVD cardiovascular
disease, CKD chronic kidney disease, glargine U100 insulin
glargine 100 units/mL, MACE major adverse cardiovascu-
lar events
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the degludec and glargine U100 groups. Like-
wise, the similar estimated reduction in the rate
of severe hypoglycemia with degludec versus
glargine U100 (rate ratios: 0.62–0.77; significant
differences were only observed for GFR cate-
gories G2 and G3) and the absence of a signifi-
cant interaction between baseline GFR
categories and randomized treatment for severe
hypoglycemia suggest that degludec use resul-
ted in a lower rate of hypoglycemia (as indi-
cated by the present analyses and the primary
DEVOTE analyses [25]) independently of the
baseline GFR. The higher risks of MACE and all-
cause mortality in patients with more advanced
baseline GFR categories were driven by higher
rates of cardiovascular death, which accounted
for 44% of MACE and 66% of all-cause
mortality.
These results are consistent with previous
findings that patients with a lower baseline GFR
are at high risk of MACE [22], all-cause mortal-
ity [32], and cardiovascular death [33]. While
many studies have not found a higher risk of all-
cause mortality in patients without CKD versus
Fig. 5 Comparison of the associations of prior CVD/
CKD/no prior CVD/CKD and treatment with degludec/
glargine U100 with the risks of MACE, cardiovascular
death, all-cause mortality and the rate of severe hypo-
glycemia. *P value for interaction between treatment and
baseline CVD and CKD status;rate of events/100 patient
years of exposure. Times from randomization to first
MACE, cardiovascular death, and all-cause mortality were
analyzed using Cox proportional hazard regression models
with treatment, baseline GFR category, and interaction
between treatment and baseline GFR category as fixed
factors. The number of severe hypoglycemic events was
analyzed using a negative binomial regression model with
log-link function and the logarithm of the duration of
observation time (100 patient years) as offset in addition
to randomized treatment, baseline GFR category, and their
interactions. Data on the proportion of patients with
events and the rate of severe hypoglycemic events are based
on observed numbers. CI confidence interval, CVD
cardiovascular disease, CKD chronic kidney disease,
glargine U100 insulin glargine 100 units/mL, MACE
major adverse cardiovascular events
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those with CKD [18, 20–22], the present study
found that even mild CKD (category G2) is
associated with a higher risk (hazard ratio 1.57,
95% CI 1.11–2.22) of all-cause mortality com-
pared with normal GFR. This finding might be
explained by the high burden of CVD in this
population (71.7%) and the persistently high
risk of cardiovascular death, accounting for
63–69% of all deaths across baseline GFR cate-
gories G2–G5. Indeed, a prior study of the
contributions of CVD and CKD to all-cause
mortality in patients with T2D found that CVD
had the strongest association with risk of all-
cause mortality in patients with and without
CKD [23]. However, results in the present study
demonstrate that prior CVD and prior CKD
were similarly associated with risk of all-cause
mortality and, if anything, prior CKD had the
strongest association.
Risk factors predisposing patients with CKD
to a greater risk of cardiovascular death include
age, diabetes prevalence, diabetes duration, and
hypertension, along with other risk factors
associated with the development of atheroscle-
rotic vascular disease [34]. In the present study,
patients with CKD (G3–5) had a higher preva-
lence of established CVD/CKD and associated
risk factors (e.g., longer diabetes duration, older
age, and higher BMI) [35] than patients without
CKD (G1–2). Other differences in terms of
baseline antihyperglycemic and cardiovascular
medications may reflect the longer duration
and more advanced state of diabetes in patients
with CKD.
If any aspect of the observed association
between baseline GFR and risk of all-cause
mortality (as reported in the present and pre-
vious studies [17, 18, 20, 21, 23, 36]) are causally
connected (in other words, not an epiphe-
nomenon), efforts to identify and limit the
progression of CKD need to be pushed to the
forefront of clinical care. The treatment of
patients with T2D and at high risk of develop-
ing CVD or CKD is complex. Glycemic control
and blood pressure management may limit the
progression of CKD, but the effects of intensive
glycemic control on cardiovascular outcomes
have been inconsistent [37–40]. While glycemic
control and blockade of the renin–an-
giotensin–aldosterone system remain
paramount in the treatment of patients with
T2D and CKD [41], the potential for antihy-
perglycemic medications to have favorable
effects on cardiovascular and renal outcomes
are being investigated [42]. For example, cana-
gliflozin [11, 43, 44], empagliflozin [12, 45],
liraglutide [15, 46], albiglutide [47], semaglutide
[13], dapagliflozin [48], and dulaglutide [49] all
have favorable effects on cardiovascular out-
comes, while some of these also slow the pro-
gression of CKD compared with placebo [50].
While there is relatively little evidence that
basal insulins differ in their ability to reduce
cardiovascular events or mortality, there is evi-
dence that basal insulins differ regarding the
associated risk of severe hypoglycemia
[25, 51, 52]. In the present study, the lack of
significant interactions between randomized
treatment and baseline groups (CKD and prior
CKD/CVD) indicate that, as was the case for the
overall DEVOTE cohort [25], the rate of severe
hypoglycemia was lower with degludec com-
pared with glargine U100 regardless of the
baseline GFR. This finding is reassuring for
clinicians, given that previous studies have
reported that patients with CKD are predisposed
to a greater risk of these events [37] and are
consequently also at a greater risk of death [53].
While the DEVOTE CVOT has provided an
ideal platform for exploring associations
between baseline GFR category and outcomes in
a T2D cohort at high cardiovascular risk, these
post hoc analyses do have limitations. These
include the likelihood that the DEVOTE eligi-
bility criteria may have resulted in a patient
cohort that is unrepresentative of the wider
population of patients with T2D and CVD. An
example of this that is relevant to the present
study was the exclusion of patients with severe
renal impairment (eGFR\30 mL/min/1.73 m2
[G4–5]) at screening. Despite this, 214 had sev-
ere renal impairment at baseline, including
seven patients with eGFR\ 15 mL/min/
1.73 m2. An additional limitation is the lack of
data on microalbuminuria at follow-up; how-
ever, as illustrated by the baseline data, CKD
with microalbuminuria/proteinuria was not
common in this cohort (37% of those with
eGFR from 30 to\60 mL/min/1.73 m2).
Indeed, while the pathogenic role of proteinuria
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in renal diseases is clear, nonalbuminuric
pathways conducive to renal function loss are
more prevalent in patients with T2D and are the
leading cause of end-stage renal disease [54].
CONCLUSION
In this large cohort of patients with T2D at high
cardiovascular risk, worsening baseline GFR
categories were associated with higher risks of
MACE, cardiovascular death, and all-cause
mortality. Patients with prior CVD, CKD, or
both were at higher risk of MACE, cardiovas-
cular death, and all-cause mortality. Only CKD
was associated with a higher rate of severe
hypoglycemia, and the risk of MACE was higher
in patients with only CVD than in those with
only CKD. The nonsignificant interactions
between randomized treatment and study out-
comes were in agreement with the results from
the overall DEVOTE CVOT analyses suggesting
that the lower rate of severe hypoglycemia with
degludec than with glargine U100 (in the
overall trial) [25] were independent of the
severity of baseline CKD. Considering the
observed association between baseline GFR
category and risk of all-cause mortality, regard-
less of randomized basal insulin assignment,
efforts to better understand this association and
methods to mitigate the incremental risk asso-
ciated with declining GFR remain important
clinical objectives.
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